New & Noteworthy

September 2019

Ready-to-Use Insulin for IV Infusion

Baxter Healthcare

Baxter has received US FDA approval of Myxredlin (insulin human in 0.9% sodium chloride injection). Myxredlin features an extended shelf life of 30 days at room temperature (77°F or 25°C) or 24 months if refrigerated (36°F to 46°F or 2°C to 8°C) in the original carton to protect from light. Provided in a standardized concentration of 100 units/100 mL in a flexible plastic container, it delivers a consistent, stable, and predictable concentration with every administration. Myxredlin is indicated for use as a short-acting human insulin to improve glycemic control in adults and pediatric patients with diabetes mellitus and is intended for use only in acute care settings under medical supervision. It is expected to be available in the United States before the end of 2019.

Baxter Healthcare Corporation

Request More Information

Current Issue